Castle Biosciences
CSTL
33.00
-0.36
-1.08%
Castle Biosciences
US · CSTL
#3242 by market cap
Listed 2019
33.00
-0.36
-1.08%
Live - 5344 symbols - heartbeat 287s ago
· 2026-10-07 19:54
After-hours
33.00
0.00%
- Market cap
- 1.01B
- P/E (TTM)i
- -51.56
- P/Bi
- 2.14
- EPSi
- -0.83
- Div yieldi
- 0.00%
- 52W posi
- 58%
Reader sentiment
Are you bullish or bearish on CSTL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.03, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.66% YoY
Margins
- Gross margin
- 79.37%
- Operating margin
- -12.44%
- Net margin
- -7.02%
Key ratios & quality
- Enterprise valuei
- 720.01M
- Altman Z-Scorei
- 6.03
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.79M | 51.87M | 62.65M | 94.09M | 137.04M | 219.79M | 332.07M | 344.23M |
| Gross profit | 17.49M | 44.56M | 52.96M | 78.26M | 105.03M | 174.81M | 271.86M | 273.20M |
| Selling & admin expenses | 16.47M | 29.84M | 48.13M | 86.74M | 143.00M | 180.15M | 200.05M | 229.32M |
| Research & development | 4.85M | 7.39M | 13.26M | 29.65M | 44.90M | 53.62M | 52.04M | 51.85M |
| Operating profit | -3.84M | 7.33M | -6.54M | -40.08M | -91.14M | -67.98M | 8.67M | -42.81M |
| Pretax profit | -6.36M | 5.35M | -10.20M | -40.01M | -68.90M | -57.37M | 21.56M | -29.51M |
| Tax | 9.00K | 72.00K | 84.00K | -8.72M | -1.77M | 101.00K | 3.32M | -5.36M |
| Net profit | -6.37M | 5.28M | -10.28M | -31.29M | -67.14M | -57.47M | 18.25M | -24.16M |
| Basic EPS | -1 | 0 | -1 | -1 | -3 | -2 | 1 | -1 |
| Diluted EPS | -0.95 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 87.99M | 86.19M | 83.04M | 87.01M | 83.68M | 103.55M |
| Gross profit | 71.61M | 68.56M | 64.34M | 68.70M | 63.15M | 79.85M |
| Selling & admin expenses | 58.62M | 58.07M | 55.91M | 56.73M | 64.90M | 66.12M |
| Research & development | 12.59M | 12.79M | 12.96M | 13.52M | 14.43M | 14.54M |
| Operating profit | -27.93M | -4.25M | -6.80M | -3.83M | -18.41M | -3.07M |
| Pretax profit | -26.27M | -143.00K | -386.00K | -2.71M | -14.41M | -1.69M |
| Tax | -423.00K | -4.67M | 115.00K | -382.00K | 109.00K | 370.00K |
| Net profit | -25.85M | 4.52M | -501.00K | -2.33M | -14.52M | -2.06M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.90 | 0.15 | -0.02 | -0.08 | -0.49 | -0.07 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 18.13M | 116.68M | 429.59M | 353.74M | 292.29M | 295.64M | 360.15M | 361.10M |
| Cash & ST investments | 4.48M | 98.85M | 409.85M | 329.63M | 258.63M | 243.10M | 293.13M | 299.51M |
| Inventory | 882.00K | 1.24M | 2.22M | 2.02M | 3.98M | 7.94M | 8.14M | 10.25M |
| Total assets | 22.41M | 119.75M | 439.33M | 462.57M | 447.33M | 453.34M | 531.24M | 578.56M |
| Total current liabilities | 6.74M | 15.29M | 20.88M | 24.89M | 36.13M | 47.67M | 49.39M | 68.68M |
| Short-term debt | -- | 5.83M | -- | 1.18M | 1.78M | 1.14M | 1.94M | 1.74M |
| Long-term debt | 24.50M | 19.29M | -- | -- | -- | -- | 9.75M | 9.64M |
| Total liabilities | 32,475,000.00 | 34,633,000.00 | 23,637,000.00 | 50,832,000.00 | 48,179,000.00 | 62,071,000.00 | 75,400,000.00 | 107,683,000.00 |
| Total equity | -10.07M | 85.11M | 415.69M | 411.74M | 399.15M | 391.27M | 455.84M | 470.87M |
| Retained earnings | -57.49M | -52.21M | -62.50M | -93.77M | -160.91M | -218.37M | -200.13M | -224.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 349.39M | 348.67M | 357.57M | 361.10M | 328.90M | 341.10M |
| Cash & ST investments | 275.15M | 275.93M | 287.54M | 299.51M | 261.69M | 266.81M |
| Inventory | 6.85M | 8.37M | 8.65M | 10.25M | 10.46M | 10.58M |
| Total assets | 501.72M | 544.73M | 562.79M | 578.56M | 547.81M | 561.18M |
| Total current liabilities | 37.27M | 50.89M | 55.31M | 68.68M | 48.76M | 56.51M |
| Short-term debt | 2.55M | 3.52M | 1.45M | 1.74M | 2.92M | 4.33M |
| Long-term debt | 8.92M | 8.10M | 10.05M | 9.64M | 8.40M | 7.16M |
| Total liabilities | 61,409,000.00 | 89,353,000.00 | 95,740,000.00 | 107,683,000.00 | 86,389,000.00 | 91,147,000.00 |
| Total equity | 440.31M | 455.38M | 467.05M | 470.87M | 461.42M | 470.03M |
| Retained earnings | -225.97M | -221.45M | -221.95M | -224.28M | -238.81M | -240.87M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -12.30M | 7.02M | 9.87M | -18.98M | -41.66M | -5.63M | 64.87M | 64.35M |
| Depreciation & amortization | 323.00K | 358.00K | 472.00K | 3.41M | 10.54M | 12.33M | 16.00M | 40.77M |
| Free cash flow | -12.57M | 6.08M | 5.11M | -22.47M | -47.29M | -19.25M | 36.54M | 28.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 65.93M | 330.04M | -- | -- | -- | -- | -- |
| Ending cash balance | 4.48M | 98.85M | 409.85M | 329.63M | 122.95M | 98.84M | 119.71M | 116.73M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -6.04M | 20.82M | 22.63M | 26.93M | -22.13M | 15.20M |
| Depreciation & amortization | 29.76M | 3.41M | 3.82M | 3.78M | 3.93M | 4.07M |
| Free cash flow | -10.78M | 11.56M | 7.80M | 19.75M | -34.58M | 6.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 89.69M | 82.23M | 85.56M | 116.73M | 63.76M | 62.12M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | 20.95 | -4.11 | -7.56 | -16.56 | -14.54 | 4.31 | -5.21 |
| ROA %i | -37.82 | 4.21 | -3.68 | -6.94 | -14.76 | -12.76 | 3.71 | -4.35 |
| ROIC %i | -- | 17.12 | -3.45 | -7.43 | -17.05 | -16.08 | 1.76 | -6.81 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -4.36 | -7.69 | -7.91 |
| EBIT margin %i | -17.93 | 19.13 | -12.08 | -42.53 | -50.27 | -26.10 | 6.67 | -8.55 |
| FCF / sales %i | -- | 11.72 | 8.16 | -- | -- | -- | 11.00 | 8.23 |
| Current ratioi | 2.69 | 7.63 | 20.58 | 14.21 | 8.09 | 6.20 | 7.29 | 5.26 |
| Quick ratioi | 2.46 | 7.42 | 20.24 | 13.94 | 7.81 | 5.90 | 6.97 | 4.99 |
| Debt / assetsi | 109.35 | 20.98 | 0.00 | 1.77 | 3.00 | 3.38 | 4.96 | 6.38 |
| LT debt / equityi | -- | 22.66 | -- | 1.71 | 2.91 | 3.63 | 5.35 | 7.47 |
| Interest coveragei | -1.80 | 2.17 | -2.87 | -40,011.00 | -4,052.18 | -5,214.00 | 38.37 | -342.19 |
| Revenue CAGR (3Y) %i | -- | -- | 65.77 | 60.43 | 38.25 | 51.95 | 52.25 | 35.94 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1.20 | -2.15 | -2.69 | -5.21 | -2.85 | -4.20 |
| ROA %i | -1.06 | -1.83 | -2.27 | -4.35 | -2.45 | -3.51 |
| ROIC %i | -3.33 | -4.46 | -4.13 | -6.81 | -4.32 | -5.12 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -0.47 | -2.86 | -5.46 | -8.55 | -5.13 | -5.27 |
| FCF / sales %i | 12.03 | 9.97 | 7.39 | 8.23 | 1.33 | -- |
| Current ratioi | 9.37 | 6.85 | 6.47 | 5.26 | 6.75 | 6.04 |
| Quick ratioi | 8.89 | 6.45 | 6.09 | 4.99 | 6.23 | 5.58 |
| Debt / assetsi | 5.15 | 6.86 | 6.60 | 6.38 | 6.70 | 6.53 |
| LT debt / equityi | 5.29 | 7.43 | 7.64 | 7.47 | 7.33 | 6.88 |
| Interest coveragei | -2.82 | -29.96 | -121.82 | -342.19 | -85.98 | -50.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Provision of testing services100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.